Ethylmalonic encephalopathy and liver transplantation: long-term outcome of the first treated patient

Giorgia Olivieri1, Diego Martinelli1, Daniela Longo2, Chiara Grimaldi3, Daniela Liccardo4, Ivano Di Meo5, Andrea Pietrobattista4, Anna Sidorina1, Michela Semeraro1 and Carlo Dionisi-Vici1*

Abstract

Background: Ethylmalonic encephalopathy (EE) is a severe intoxication-type metabolic disorder with multisystem clinical features and leading to early death. In 2014, based on the promising results obtained by liver-targeted gene therapy in Ethe1−/− mouse model, we successfully attempted liver transplantation in a 9-month-old EE girl. Here we report her long-term follow-up, lasting over 6 years, with a comprehensive evaluation of clinical, instrumental and biochemical assessments.

Results: Neurological signs initially reverted, with a clinical stabilization during the entire follow-up course. Accordingly, gross motor functions improved and then stabilized. Psychomotor evaluations documented an increasing communicative intent, the acquisition of new social skills and the capability to carry out simple orders. Neurophysiological assessments, which included EEG, VEP/ERG and BAEPs, remained unchanged. Brain MRI also stabilized, showing no further lesions and cerebral atrophy improvement. Compared to pre-transplant assessments, urinary ethylmalonic acid strikingly reduced, and plasma thiosulphate fully normalized. The child maintained good clinical conditions and never experienced metabolic crises nor epileptic seizures.

Conclusions: The long-term follow-up of the first EE transplanted patient demonstrates that liver transplantation stabilizes, or even improves, disease course, therefore representing a potentially elective option especially in early-diagnosed patients, such as those detected by newborn screening, before irreversible neurological damage occurs.

Keywords: Liver transplantation, Ethylmalonic encephalopathy, ETHE1, Thiosulphate, Motor function

Background

Ethylmalonic Encephalopathy (EE) was first described in 1991 as a severe multisystem disorder, characterized by early-onset encephalopathy, petechial purpura, orthostatic acrocyanosis, chronic diarrhea and progressive spasticity, biochemically associated with ethylmalonic aciduria, elevated C4- and/or C5- acyl-carnitine esters, and hyperlactacidemia [1, 2]. Some years later, ETHE1 was identified as the causative gene. ETHE1 encodes for a protein targeted into mitochondria [3], whose function was then elucidated in playing a key role in hydrogen sulphide (H2S) detoxification as a sulphur dioxygenase [4]. This newly discovered metabolic pathway is ubiquitously expressed in humans, and it is involved in the detoxification of H2S, mainly produced by anaerobic bacteria in the large intestine and, to a lesser extent, by sulphurated aminoacids catabolism in peripheral tissues [5]. Therefore, ETHE1 mutations cause sulphur dioxygenase deficiency, which lead to the toxic accumulation of H2S and its metabolites in tissues and body fluids, making EE an “intoxication type” metabolic disease [6]. H2S and its
stable derivative thiosulphate have a strong vasoactive and vasotoxic effect [7], causing a widespread multisystem endothelial vascular damage, mainly located in brain, skin, muscle and gastrointestinal tract [8]. Moreover, H₂S accumulation exerts an inhibitory effect on several mitochondrial enzymes, including cytochrome C oxidase (COX) and short chain acyl-CoA dehydrogenase (SCAD), thus explaining the characteristic biochemical abnormalities [3, 4]. Secondary COX deficiency mainly affects energetic metabolism in brain and muscle, causing lactic acidosis, stroke-like encephalopathic crises, epileptic seizures and myopathy [8], while SCAD inhibition causes the elevation of ethylmalonic acid and of C4- and C5- acyl-carnitine esters [1, 2].

Few studies reported the potential beneficial effects of a combined treatment with N-acetylcysteine (NAC), metronidazole (MTZ), and the dietary restriction of the sulphur containing aminoacid methionine in decreasing serum thiosulphate and ameliorating the clinical course (Table 1) [9–11]. However, these approaches have a limited impact on the natural disease history in patients with severe EE [12]. In this regard, a spectrum of clinical severity exists in EE, which includes, beside the severe form presenting with multisystem clinical features and leading to early death, a handful of cases with an “atypical” mild phenotype, characterized by pyramidal dysfunction, minor cognitive involvement, no systemic signs and longer survival [13–15].

In 2012, a liver-targeted gene therapy was attempted in recombinant Ethe1−/− mouse model with encouraging results. This innovative approach, based on restoring the expression of ETHE1 in the liver, allowed a marked increase of hepatic ETHE1 function and the clearance of most of the circulating H₂S from intestinal blood. As a fact, thiosulphate levels decreased to nearly normal levels with a significant improvement in treated animals’ survival time [16].

On this basis, we successfully attempted a living-donor orthotopic liver transplantation in a 9 month-old child with the “classical” severe EE phenotype [17]. Within the first year of follow-up, her biochemical abnormalities promptly reversed and psychomotor development improved. Here we report her long-term post-transplant follow-up, lasting over 6 years, with a comprehensive description of impact of liver transplantation on clinical, neurophysiological, neuroradiological and biochemical outcomes.

**Case report**

**The patient**

Clinical and biochemical data about the first year of follow-up have been previously reported [17]. Briefly, the child was referred to the Metabolic Unit of Bambino Gesù Hospital in Rome at the age of 7 months, as she was diagnosed with EE due to ETHE1 homozygous c.131-132delAG mutation. The clinical picture included moderate psychomotor delay, axial hypotonia and lower limb spasticity, associated to severe petechial purpura and orthostatic acrocyanosis. Biochemically she presented elevation of C4- and C5-acylcarnitines, plasma thiosulphate and urinary ethylmalonic acid (Fig. 1). Brain MRI showed basal ganglia involvement and mild cortical atrophy (Fig. 2a). Treatment with NAC (100 mg/kg/day), MTZ (30 mg/kg/day) and carnitine (100 mg/kg) was rapidly started. With the aim to improve the natural course of the disease, based on the promising results obtained by liver-targeted gene therapy in the mouse model, she

![Fig. 1 Longitudinal biochemical assessments. Plasma thiosuphates and urinary ethylmalonic acid showed a striking and stable improvement after liver transplantation, reaching values close to normal levels; blood lactate values showed a reduced trend. Solid lines indicate the upper reference values](https://example.com/fig1.png)
Table 1  Outcome in EE patients treated by liver transplantation compared to medical therapies (follow-up ≥ 1 year)

| Reference | Genotype | Age at onset | Phenotype | Liver Transplant age | Low protein diet start–end | NAC therapy start–end | MTZ Therapy start–end | EMA baseline/ follow-up | Reported outcome at follow-up |
|-----------|----------|--------------|-----------|----------------------|---------------------------|------------------------|------------------------|--------------------------|-------------------------------|
| Present Case | c.131_132delAG/c.131_132delAG | 7 m | Severe | 7 y | 9 m | 7 m–ongoing | 7 m–21 m | 205/40 | Disease stabilization, achievement of cognitive and social skills (says few words, sits unaided), persistence of diarrhea and skin signs, MRI improvement of atrophy |
| [28] | del exon 4/del exon 4 | NBS | Severe | 2.3 y | 19 m | 13 m–ongoing | 13 m–ongoing | | Improvement of social and language skills, sits unaided, babbling |
| [28] | c.487C>T/c.487C>T | NBS | Severe | 2.9 y | 13 m | 2 m–ongoing | 2 m–ongoing | 153/31 | Seven months after transplant episode of metabolic decompensation, then slow improvements in motor, verbal and social skills (sit unaided, says few simple words) |
| [29] | c.375+5G>A/c.462 T>A | 1 m | Severe | 32 y | 18 m | 15 m–18 m | 15–20 m | 179/70.7 | No remarkable general amelioration, disease stabilization, quadriplegia, achievement of few words, head control, persistence of skin signs and diarrhea, MRI stabilization |
| [11] | c.131_132delAG/c.566delG | NBS | Severe | 2.1 y | 8 m–ongoing | 1.5 m–ongoing | 1.5 m–ongoing | 617.7/383.9 | Slow developments in motor and verbal skills, sits unaided, says few words, mild skin signs, no diarrhea |
| Reference | Genotype       | Age at onset | Phenotype | Liver Transplant age | Low protein diet start–end | NAC therapy start–end | MTZ Therapy start–end | EMA baseline/ follow-up | Reported outcome at follow-up |
|-----------|----------------|--------------|-----------|---------------------|---------------------------|-----------------------|------------------------|------------------------|-------------------------------|
| [32]      | c.448G>A/c.448G>A | 10 m         | Severe    | 2.5 y               | 15 m–ongoing              | 15 m–ongoing           | 15 m–ongoing           | Disease stabilization, psychomotor achievements, says simple words, walks with aid |
| [11]      | c.505+1G>A/c.505+1G>A | NBS         | Severe    | 2.1 y               | 2 m–ongoing               | 2 m–ongoing            | 586/352.2              | Sits unaided, poor growth, diffuse skin signs, non-verbal achievement, good visual attention, no diarrhea |
| [15]      | c.79C>A/c.79C>A | 10 y         | Mild      | 19 y                | 16 y–ongoing              | 16 y–ongoing           | 72/74                  | Improvement of mobility and speech, at 17 years episode of acute decompensation with seizures followed by regain of functionalities |
| [31]      | c.3G>T/c.3G>T | 5 y          | Mild      | 15 y                | 11 y–ongoing              | 11 y–ongoing           | 46/24                  | Improved diarrhea and QoL, worsening of paraparesis, normal IQ, normal MRI |

EMA Ethylmalonic acid, mean values expressed as mmol/mol creatinine, MTZ metronidazole, NAC N-acetylcysteine, NBS newborn screening, QoL quality of life
underwent liver transplantation at the age of 9 months, by receiving the left lobe from her heterozygous mother.

**Methods**

After transplantation, the patient underwent longitudinal clinical and neurological evaluations. Motor function assessment were performed by the Gross Motor Function Measure 66-item version (GMFM-66) [18]. Psychomotor development was assessed by the Mental Developmental Griffiths’ Scales (MDGS). Neurophysiological studies included electroencephalogram (EEG), visual evoked potentials (VEPs) with electroretinogram (ERG), and brain steam auditory evoked potentials (BAEPs). Target metabolites, consisting of plasma thiosulphate and urinary ethylmalonic acid, were measured by HPLC and gas-chromatography/mass-spectrometry respectively. Neuroradiological assessments by brain MRI were performed at 1, 2, 3 and 5 years of follow-up. Post-transplantation data were compared to pre-transplantation ones, in order to verify the effect of liver transplantation on the natural history of the disease.

**Results**

**General clinical course**

The child maintained good clinical conditions throughout over 6 years of follow-up. Petechial purpura and orthostatic acrocyanosis persisted, while metabolic crises and epileptic seizures never occurred. Her swallowing function remained unchanged and, to date, is orally fed with her parent’s help. She receives standard immunosuppressive treatment with tacrolimus, antioxidant therapy with NAC (100 mg/kg/day) and low-dose carnitine supplementation (30 mg/kg/day). After transplantation, no dietary restrictions have been applied. To avoid resistances and potential side effects, the initial pre-transplant bowel decontamination therapy with MTZ alone was shifted to a poly-therapy, consisting in the weekly rotation of different antibiotics (i.e. cefixime, ciprofloxacin, rifaximin and nystatin). As for chronic diarrhea, we observed a fluctuating ameliorating trend in terms of stool frequency when courses with different antibiotics included cefixime and ciprofloxacin, which were therefore mainly maintained.

Bicarbonate supplementation was started to correct mild metabolic acidosis, likely related to the side effects of immunosuppressive treatment with tacrolimus on kidney function.

**Neuromotor assessment**

Before liver transplantation, the patient presented axial hypotonia, pyramidal signs at lower limbs and the inability to sit unsupported. Within the first 6 months after transplantation, she progressively reached new motor skills, including the ability to sit unaided, push herself up to her forearms and roll over. At 2 years of follow-up she was able to maintain static standing with an external support, as long as she was placed in standing position with leg braces. Up to the fourth year of follow-up, she was able to walk forward with an external support at upper limbs. At the same time, under an intensive rehabilitation program, she strengthened other motor skills, improving motor functions at the trunk and upper limbs. Consistent with the clinical outcome, GMFM-66 total score rapidly improved from pre-transplantation value of 12–20% and 32%, respectively 6 months and one year later, and then stabilized, scoring 31% at 3 years (12°p), 30% at 5 years (9°p), 32% at 6 years (10°p) (Fig. 3).

**Cognitive assessment**

Longitudinal MDGS scored a mental age of 10 months versus 21 months of chronological age at 1 year of follow-up, and of 17 months versus 4.2 years of
chronological age at 3 years of follow-up, consistent with a severe psychomotor delay. Further cognitive evaluations were later attempted at 5 and 6 years of follow-up. At these times, the increasing gap between the test requests accorded to the chronological age and the objectivable performances make not possible to obtain standardized scores. Manual skills resulted grossly affected by peripheral muscle weakness, and the absence of verbal language hampered to accurately quantify the child’s level of comprehension. However, at the 5th year of follow-up, she presented a very good visual interaction and the capability to carry out simple one-step orders (e.g. “give me that toy” or “move that object from here to there”) and at the 6th year she showed a good communicative intent, mainly focused on gesture, and the capability to perform simple cognitive tasks (e.g. recognizing the main colors or some animals) with slight improvements in verbal skills as well, allowing to pronounce few simple words (e.g. “mom”, “water”, etc.).

**Neurophysiological studies**

VEPs/ERG and BAEPs resulted normal at baseline and remained unchanged at follow-up controls, which were performed annually. Awake-EEG showed a slight and diffuse slowdown of the background activity over years, while epileptic paroxysmal were never recorded.

**Neuroradiological findings**

Brain MRI performed before transplantation documented a mild brain atrophy and initial bilateral involvement of basal ganglia. After liver transplantation, longitudinal MRI assessment showed a progressive reduction of periencephalic spaces up to complete resolution of brain atrophy. With regard to basal ganglia, a very slight progression of the left putamen lesion occurred between the 1st and the 3rd year of follow-up, and then stabilized (Fig. 2).

**Biochemical results**

Before liver transplantation, plasma thiosulphate levels were grossly elevated (26.8±13.5 µmol/L; nv < 4.0). Afterwards, we observed a rapid ameliorating trend, with a complete and stable normalization at follow-up (range 2.2–2.4 µmol/L). Consistently, urinary ethylmalonic acid values dropped from 205.8±66.2 mmol/mol creatinine (nv < 20.0) to 40.0±1.4 mmol/mol creatinine at follow-up. Blood lactate values also reduced from 6.4±2.8 mmol/L (nv < 2.2) to 4.3±1.0 mmol/L (Fig. 1).

**Discussion**

This report shows that liver transplantation stabilized the long-term disease course in a severe case of EE, thus making this therapeutic option a suitable approach in EE, as seen in other intoxication type metabolic diseases [19, 20]. The liver transplant effectiveness in EE relies on
restoring hepatic deficient sulphur dioxygenase activity, thereby providing the hepatic filtering support to clear most of the circulating H$_2$S, grossly produced in the gastrointestinal tract [7]. Our patient presented a homozygous frameshift mutation (c.131–132delAG), responsible for a premature biallelic stop codon at the ET$\text{HE} 1$ second exon, with deleterious impact on protein expression [17].

Consistent with the genotype, she presented the “classical” severe form of EE, with a very poor neurological outcome and a short life expectancy. However, her clinical course was significantly modified by liver transplantation associated with maintenance of standard medical therapy, which allowed clinical improvement and long-lasting stabilization. Different from the usual disease course, she never experienced metabolic crises nor epileptic seizures, while became able to achieve relevant improvements in both motor and cognitive skills. At the age of 4 years, when she reached her higher motor function ability, she was classified, according to the Gross Motor Function Classification System (GMFCS) [21], as having a level IV severity disability. At a longer-term follow-up, her gross motor function curve stabilized, remaining within the same percentile trajectory. This trend is consistent with a static neurological disease, such as an infantile cerebral palsy [21], and is far very different from what observed in severe EE [12]. Accordingly, neurophysiological assessments documented the integrity of the visual and auditory networks, and EEG recorded no epileptic paroxysmal, which is different from the natural course of the diseases [8, 22–25]. Post-transplant brain MRI documented the progressive resolution of cortical atrophy, along with a transient slight progression of a left putaminal lesion, which later stabilized.

Biochemically, plasma thioussulphate, the primary metabolite biomarker of EE, fully normalized, and urinary excretion of ethylmalonic acid markedly reduced up to an almost complete normalization. Blood lactate levels mildly improved as well. The lower impact of liver transplantation on skin and gastrointestinal manifestations, suggests that not only the circulating level of H$_2$S (and of its derivative thioussulphate) contributes to the multisystem clinical phenotype. It is likely that also the local production of toxic compounds in different tissues maintains unchanged some disease symptoms [26]. MTZ therapy was discontinued one year after transplantation due to patient’s intolerance (abdominal pain), to avoid antibiotic resistance, for a better effect on chronic diarrhea obtained with different molecules and to prevent the potential side effect on peripheral nerve when used for prolonged periods at high doses [27].

Following our original report [17], three further EE patients underwent liver transplantation [28, 29]. Tam et al. [28] reported on two children with severe EE, identified by newborn screening and transplanted at the age of 19 and 13 months respectively, when their neurological picture was already compromised. The first patient, carrying a homozygous deletion of exon 4 of ET$\text{HE} 1$, received orthotropic liver transplantation from a cadaveric donor and was reported to show a clear improvement of his neurological status over the first nine months after transplantation. The second one, carrying a homozygous severe pathogenic variant in ET$\text{HE} 1$ (c.487C>T, p.R163W), had an elder affected sibling who died at the age of 2 after an encephalopathic episode triggered by a viral infection. After transplantation, a neurological improvement occurred, but seven months later, in the context of a viral gastroenteritis, he presented a severe encephalopathic crisis with a metabolic stroke requiring intubation. Brain MRI showed new extensive lesions in cerebellum, white matter, bilateral striatum and corpus callosum. Nevertheless, at 22 months of follow-up, his clinical outcome was reported to be stable.

After transplantation both patients continued NAC and MTZ, and one carnitine therapy. Biochemically, they showed a reduction of urinary excretion of isobutyryl- and 2-methylbutyryl-glycine, with no changes in plasma ethylmalonic acid values in one. Post-transplant data on the primary biomarker plasma thioussulphate and on urinary ethylmalonic acid were not reported in the study [28]. A further EE patient, compound heterozygous for a known pathogenic mutation (c.375+5G>A) and a novel mutation (c.462T>A, p.D154E) in ET$\text{HE} 1$, received liver transplant with a reduced-size left lateral lobe donated by his heterozygous mother at the age of 18 months [29]. Before transplant the neurological examination revealed marked axial hypotonia, muscle weakness, increased deep tendon reflexes, clonus, and bilateral Babinski sign with fronto-temporal atrophy and multiple bilateral symmetrical lesions of basal ganglia at brain MRI. During 20 months of follow-up, brain MRI suggested a certain improvement in basal ganglia lesions. Clinically the patient still presented developmental delay and neurologic disability, with a mild amelioration of petechiae and ecchymosis and without improvement of chronic mucoid diarrhea and orthostatic acrocyanosis. After transplantation, MTZ and carnitine therapy was initially continued with clear improvement of metabolite levels. Subsequently, metronidazole was interrupted due to patient’s intolerance resulting in the increase of urinary EMA levels while 2-methylsuccinic acid levels gradually restored to normal.

The long-term outcome in the four patients treated by liver transplantation in comparison with those receiving medical therapies (i.e. diet, antioxidant and decontaminating drugs) with a follow-up $\geq$ 1 year is shown in Table 1. Despite an overall limited experience, liver transplantation
improved or stabilized the disease course in at least two out of four patients. As seen in other metabolic diseases, liver transplantation although not allowing to fully cure the disease may impact favorably on its course [30]. After transplantation, metronidazole (or intestinal antibiotic therapy) and carnitine therapy is advisable to further improve the metabolic profile by reducing the major offending metabolites. Taken together, these data suggest that liver transplantation should be considered an elective therapeutic option in EE, especially in early diagnosed patients, and in particular in those identified by newborn screening, before irreversible neurological damages occur. For a better understanding of the impact of liver transplantation on EE, a multidisciplinary approach in the long-term management of disease-targeted therapies, immunosuppressive regimen, and in monitoring biochemical and neurological outcomes is advisable.

Conclusions
This case history, reporting the long-term follow-up in the first transplanted severe EE patient, confirms that liver transplantation represents the most effective therapeutic option to be considered in early diagnosed EE cases, before the occurrence of progressive and irreversible neurological damages.

Acknowledgements
We thank the Association La Vita e un Dono for supporting the fellowship of Dr. Giorgia Olivieri. The Division of Metabolism Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy is affiliated member of the European Reference Network for hereditary Metabolic Disorders (MetaBERN) and associated partner of the Unified European Registry for Inherited Metabolic Disorders (U-IMD), of the European Registry and network for Intoxication type Metabolic Diseases (E-IMD), and of the European Network and Registry for Homocystinurias and Methylation Defects (E-HOD).

Authors’ contributions
Giorgia Olivieri contributed to design the study, collected the clinical data, contributed to interpretation of the neuropsychological and neuro-radiological data and drafted the manuscript. Diego Martinelli, Chiara Grimaldi, Daniela Dionisi-Vici designed and supervised the study, contributed to interpretation of the data and revised the manuscript. All authors read and approved the final manuscript.

Funding
This work was supported with the funds Ricerca Corrente by the Italian Ministry of Health and by the no-profit Association La Vita è un Dono.

Availability of data and materials
All data generated and analysed during this study are included in this published article.

Declarations

Ethics approval and consent to participate
The study was approved by the Ethics Committee of the Infantile Bambino Gesù Hospital. Written informed consent was provided to our patient’s parent, prior to participation in the study.

Consent for publication
Written informed consent for the publication of the patient’s clinical details and clinical images was obtained from the patient’s parent. A copy of the consent form is available for review by the Publisher of this journal.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Division of Metabolism, Bambino Gesù Children’s Hospital, IRCCS, Piazza S. Onofrio 4, 00165 Rome, Italy. 2 Neuroradiology Unit, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy. 3 Division of Abdominal Transplantation and Hepatobiliopancreatic Surgery, Bambino Gesù Children’s Research Hospital IRCCS, Rome, Italy. 4 Division of Hepatology and Gastroenterology, Bambino Gesù Children’s Research Hospital IRCCS, Rome, Italy. 5 Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

Received: 18 January 2021 Accepted: 11 May 2021
Published online: 19 May 2021

References
1. Burlina A, Zacchello F, Dionisi-Vici C, et al. New clinical phenotype of branched-chain acyl-CoA oxidation defect. Lancet. 1991;338:1522–3.
2. Burlina AB, Dionisi-Vici C, Bennett MJ, et al. A new syndrome with ethylmalonic aciduria and normal fatty acid oxidation in fibroblasts. J Pediatr. 1994;124:79–86.
3. Tiranti V, D’Adamo P, Briem E, et al. Ethylmalonic encephalopathy is caused by mutations in ETHE1, a gene encoding a mitochondrial matrix protein. Am J Hum Genet. 2004;74:239–52.
4. Tiranti V, Visconi C, Hildebrandt T, Di Meo I, et al. Loss of ETHE1, a mitochondrial dioxygenase, causes fatal sulfide toxicity in ethylmalonic encephalopathy. Nat Med. 2009;15:220–5.
5. Kabil O, Banejee R. Redox biochemistry of hydrogen sulfide. J Biol Chem. 2010;285:21903–7.
6. Saudubray JM, Garcia CA. Clinical approach to inborn errors of metabolism in pediatrics. In: Saudubray JM, Baumgartner MR, Walter J, editors. Inborn metabolic diseases, diagnosis and treatment. Berlin: Springer; 2016. p. 3–70.
7. Szabo C. Hydrogen sulphide and its therapeutic potential. Nat Rev Drug Discov. 2007;6:917–35.
8. Garavaglia B, Colamaria V, Carrara F, Tonin P, Rimoldi M, Uziel G. Muscle cytochrome c oxidase deficiency in two Italian patients with ethylmalonic aciduria and peculiar clinical phenotype. J Inherit Metab Dis. 1994;17:301–3.
9. Visconi C, Burlina AB, Dweikat I, et al. Combined treatment with oral metronidazole and N-acetylcysteine is effective in ethylmalonic encephalopathy. Nat Med. 2010;16:869–71.
10. Klg M, Dedecoluğlu Ö, Göçmen R, Kesici S, Yüksel D. Successful treatment of a patient with ethylmalonic encephalopathy by intravenous N-acetylcyteine. Metab Brain Dis. 2017;32:293–6.
11. Boyer M, Sowa M, Di Meo I, et al. Response to medical and a novel dietary treatment in newborn screen identified patients with ethylmalonic encephalopathy. Mol Genet Metab. 2018;124:57–63.
12. Martinelli D, Catteruccia M, Piemonte F, et al. EPI-743 reverses the progression of the pediatric mitochondrial disease genetically defined Leigh syndrome. Mol Genet Metab. 2012;107:383–8.

13. Pigeon N, Campeau PM, Cyr D, Lemieux B, Clarke JT. Clinical heterogeneity in ethylmalonic encephalopathy. J Child Neurol. 2009;24:991–6.

14. Yucel-Yilmaz D, Ozgul RK, Pektas E, Serdaroglu E, Yalnizoglu D, Dursun A. Ethylmalonic encephalopathy without ethylmalonic aciduria. J Inherit Metab Dis. 2016;39(suppl 1):S137.

15. Kitzler TM, Gupta IR, Osterman B, et al. Acute and chronic management in an atypical case of ethylmalonic encephalopathy. J Inherit Metab Dis Rep. 2019;4:57–63.

16. Di Meo I, Auricchio A, Lamperti C, Burlina A, Visconi C, Zeviani M. Effective AAV-mediated gene therapy in a mouse model of ethylmalonic encephalopathy. EMBO Mol Med. 2012;4:1008–14.

17. Dionisi-Vici C, Diodato D, Torre G, et al. Liver transplant in ethylmalonic encephalopathy: a new treatment for an otherwise fatal disease. Brain. 2016;139:1045–51.

18. Russell DJ, Rosenbaum PL, Avery LM, Lane M. Gross motor function measure (GMFM-66 and GMFM-88) user’s manual. London: MacKeith Press; 2002.

19. Molema F, Martinelli D, Hörster F, et al. Liver and/or kidney transplantation in amino and organic acid-related inborn errors of metabolism: an overview on European data. J Inherit Metab Dis. 2020. https://doi.org/10.1002/jimd.12318.

20. Oishi K, Arnon R, Wasserstein MP, Diaz GA. Liver transplantation for pediatric inherited metabolic disorders: considerations for indications, complications, and perioperative management. Pediatr Transplant. 2016;20:756–69.

21. Hanna SE, Bartlett DJ, Rivist LM, Russell DJ. Reference curves for the gross motor function measure: percentiles for clinical description and tracking over time among children with cerebral palsy. Phys Ther. 2008;88:596–607.

22. Papetti L, Garone G, Schettini L, et al. Severe early onset ethylmalonic encephalopathy with West syndrome. Metab Brain Dis. 2015;30:1537–45.

23. Peake RW, Rodan LH. Ethylmalonic aciduria in an infant with neurological and skin presentation. Clin Chem. 2017;63:1771–3.

24. Govindaraj P, Sankaran BP, Nagappa M, et al. Child neurology: ethylmalonic encephalopathy. Neurology. 2020;94:1336–9.

25. Grosso S, Mostardini R, Farnetti MA, et al. Ethylmalonic encephalopathy: further clinical and neuroradiological characterization. J Neurol. 2002;249:1446–50.

26. Giordano C, Visconi C, Orlandi M, et al. Morphologic evidence of diffuse vascular damage in human and in the experimental model of ethylmalonic encephalopathy. J Inherit Metab Dis. 2012;35:451–8.

27. Diodato D, Olivieri G, Pro S, et al. Axonal peripheral neuropathy in propionic acidemia: a severe side effect of long-term metronidazole therapy. Neurology. 2018;91:565–7.

28. Tam A, Al Dhahihi NS, Mysoore K, et al. Improved clinical outcome following liver transplant in patients with ethylmalonic encephalopathy. Am J Med Genet A. 2019;179:1015–9.

29. Zhou GP, Qu W, Zhu ZJ, et al. Compromised therapeutic value of pediatric liver transplantation in ethylmalonic encephalopathy: a case report. World J Gastroenterol. 2020;26:6295–303.

30. McKiernan PJ, Ganoza A, Squires JE, et al. Evolving trends in liver transplant for metabolic liver disease in the United States. Liver Transpl. 2019;25:911–21.

31. Ersoy M, Tiranti V, Zeviani M. Ethylmalonic encephalopathy: clinical course and therapy response in an uncommon mild case with a severe ETHE1 mutation. Mol Genet Metab Rep. 2020;25:100641.

32. Cardelo Autero N, Cordón Martínez AM, Ramos-Fernández JM. Ethylmalonic encephalopathy: phenotype–genotype description and review of its management. Neurologia. 2021;36(2):10009–18.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.